tiprankstipranks
Advertisement
Advertisement
InflaRx Raises $150 Million in Underwritten Share Offering Filed in Early May 2026
PremiumCompany AnnouncementsInflaRx Raises $150 Million in Underwritten Share Offering Filed in Early May 2026
3M ago
InflaRx to develop izicopan in AAV
Premium
The Fly
InflaRx to develop izicopan in AAV
3M ago
InflaRx Refocuses Izicopan on Vasculitis and Renal Diseases With Funding Runway to 2029
Premium
Company Announcements
InflaRx Refocuses Izicopan on Vasculitis and Renal Diseases With Funding Runway to 2029
3M ago
InflaRx assumed with an Outperform at Oppenheimer
PremiumThe FlyInflaRx assumed with an Outperform at Oppenheimer
4M ago
InflaRx Shareholders Approve Capital, Governance Changes and 2026 Incentive Plan at April AGM
Premium
Company Announcements
InflaRx Shareholders Approve Capital, Governance Changes and 2026 Incentive Plan at April AGM
4M ago
InflaRx Highlights New Izicopan Data Showing No CYP3A4 Time-Dependent Inhibition
Premium
Company Announcements
InflaRx Highlights New Izicopan Data Showing No CYP3A4 Time-Dependent Inhibition
4M ago
InflaRx Shifts Strategy to Izicopan as 2025 Results Extend Cash Runway to 2027
PremiumCompany AnnouncementsInflaRx Shifts Strategy to Izicopan as 2025 Results Extend Cash Runway to 2027
5M ago
InflaRx reports FY25 EPS (EUR 0.68) vs. (EUR 0.78) last year
Premium
The Fly
InflaRx reports FY25 EPS (EUR 0.68) vs. (EUR 0.78) last year
5M ago
IFRX Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
IFRX Earnings this Week: How Will it Perform?
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100